Armistice reports 9.99% stake in Imunon
Imunon, Inc. reported that Armistice Capital, LLC and Steven Boyd beneficially own 349,917 shares of common stock, representing 9.99% of the class as of 12/31/2025.
Rhea-AI Filing Summary
Imunon, Inc. reported that Armistice Capital, LLC and Steven Boyd beneficially own 349,917 shares of common stock, representing 9.99% of the class as of 12/31/2025. The filing states shared voting and dispositive power over the 349,917 shares and notes that the Master Fund has the right to receive dividends or sale proceeds.
Positive
- None.
Negative
- None.
Insights
Armistice reports a 9.99% stake in Imunon with shared voting power.
The filing lists 349,917 shares beneficially owned with shared voting and shared dispositive power as of 12/31/2025. This reflects a passive ownership disclosure under Schedule 13G rather than an active Schedule 13D acquisition narrative.
The statement also notes the Master Fund's right to receive dividends or sale proceeds; subsequent filings would clarify if ownership or intent changes.
Disclosure signals a near-10% stake by an institutional investor, useful for shareholder registers and proxy tallies.
The report attributes shared voting and dispositive power to Armistice/Steven Boyd for the 349,917 shares. The filing is a joint filing by Armistice Capital, LLC and Steven Boyd and is signed on 02/17/2026.
Any effect on governance depends on future filings or voting activity; timing and any planned transactions are not stated here.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake did Armistice Capital report in IMNN?
Does the Schedule 13G indicate control of Imunon (IMNN)?
When was the IMNN ownership disclosure signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.